NCT07299019Phase 3Recruiting

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Study sponsor: Zenas BioPharma (USA), LLC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-06Estimated
Enrollment · participants990Estimated
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source

· 1 field changed

Planned enrollment increased by 660 participants

Before: 330 participants (planned). After: 990 participants (planned).

Check registry source